Medicines

The medicines sector is characterised by a few large pharmaceutical companies and a large number of SME “biotech” companies.

Support for companies of all sizes is provided by the Health Team across the sector but particularly linked with the manufacturing of pharmaceuticals and advanced therapeutics. Members of the Health Team are closely aligned with the Medicines Manufacturing Industry Partnership and the Bioindustry Association.

KTN also organises the Medicines Manufacturing Challenge Community. Its core goal is to accelerate the outcomes from the medicines manufacturing ISCF Challenge which has seen £146m invested in different projects, including the Medicines Manufacturing Innovation Centre and Advanced Therapy Treatment Centres.

Our Medicines Expert

Karen Wilkinson

Read full profile

Funding Opportunities

Horizon Europe Covid-19 funding opportunities

Four linked calls for Covid-19 related research and innovation actions, with a total budget of over €100m; these cover clinical trials, cohort management and monitoring, research infrastructure, and open data sharing.

Opens: 13/04/2021 Closes: 06/05/2021

Explore Further

Medicines and Diagnostics Manufacturing Transformation Fund

New £20 million fund to grow UK life sciences manufacturing opens for applications

Opens: 07/04/2021 Closes: 30/06/2021

Explore Further

View All Funding Opportunities

Recorded: 31st March

Medicines Manufacturing Challenge Community Event 2021

This Medicines Manufacturing Challenge Community showcase event, delivered by Knowledge Transfer Network, is an opportunity to learn more about the latest projects and the research and infrastructure developments that will accelerate the development and manufacture of vital advanced therapies, medicines and vaccines.

Watch Now

News

08.04.2021

Horizon Europe Cluster 1: Health Work Programme

Horizon Europe is the next European Funding Framework Programme following on from its predecessor Horizon 2020. It will run for seven years from 2021 to 2027. The total budget set for the programme is €95.5 billion. There are six Clusters under Pillar 2: Global Challenges and European Industrial Competitiveness. Health is Cluster 1.

12.03.2021

National Core Studies Immunity Programme Initiative: Next generation assays to assess cellular immunity against SARS-CoV-2

The Covid-19 National Core Studies (NCS) Immunity programme, in collaboration with Innovate UK and MRC is looking to assess cellular immunity against SARS-CoV-2. To support this work, KTN is organising a workshop on 15th April, which will include presentations from the NCS Immunity programme.

View All Related News

Programmes related to Medicines

View all our programmes

Medimap: End-to-end medicines supply chain map

Medimap is a new interactive reference tool for the UK medicines sector, mapping and categorising over 3,000 sites of organisations engaged in or supporting the end-to-end supply chain for medicines.

Learn More

Medicines Manufacturing Challenge Community

Supporting manufacturers of medicines in order to grow the UK economy